摘要
目的:分析利拉鲁肽对多囊卵巢综合征患者抗缪勒氏管激素及代谢状态的影响。方法:选取2018年1月-2019年12月在本院接受治疗的102例多囊卵巢综合征患者。按照随机数字表法将其分为研究组和对照组,每组51例。其中对照组给予常规口服炔雌醇环丙孕酮片进行治疗,研究组在对照组基础上联合口服利拉鲁肽。两组均连续治疗3个月后,对比两组临床疗效,对比两组治疗前后激素指标、代谢指标,观察排卵及妊娠情况。结果:研究组治疗总有效率为94.12%,高于对照组的76.47%,差异有统计学意义(P<0.05)。两组治疗前激素指标对比,差异均无统计学意义(P>0.05);研究组治疗后AMH、LH、FSH、T水平均低于对照组,差异均有统计学意义(P<0.05)。两组治疗前代谢指标对比,差异均无统计学意义(P>0.05);研究组治疗后TC、TG、HDL-C、LDL-C水平均优于对照组,差异均有统计学意义(P<0.05)。研究组排卵率、妊娠率均明显高于对照组,差异均有统计学意义(P<0.05)。结论:利拉鲁肽在多囊卵巢综合征患者中的应用效果较好,可有效改善其抗缪勒氏管激素等激素指标及代谢状态,还可有效提高其排卵率、妊娠率,临床应用价值较高。
Objective:To analyze the effect of Liraglutide on the anti-Mullerian hormone and metabolic status of patients with polycystic ovary syndrome.Method:A total of 102 patients with polycystic ovary syndrome who treated in our hospital from January 2018 to December 2019 were selected.According to the random number table method,they were divided into the study group and the control group,51 cases in each group.The control group was given conventional oral Ethinylestradiol Cyproterone tablets for treatment,and the study group was given a combination of oral Liraglutide on the basis of the control group,two groups treated for 3 months.The clinical efficacy of two groups were compared,the hormone indicators and metabolic indicators before and after treatment were compared between two groups,and ovulation and pregnancy conditions were observed.Result:The total effective rate of treatment in the study group was 94.12%,which was higher than 76.47%of the control group,there was statistical significance(P<0.05).There were no statistical significance in the hormone indexes between two groups before treatment(P>0.05).After treatment,the levels of AMH,LH,FSH and T in the study group were lower than those in the control group,there were statistical significance(P<0.05).The metabolic indexes of two groups before treatment were compared,there were no statistical significance(P>0.05).After treatment,the levels of TC,TG,HDL-C and LDL-C in the study group were all superior to those in the control group,there were statistical significance(P<0.05).The ovulation rate and the pregnancy rate in the study group were significantly higher than those in the control group,there were statistical significance(P<0.05).Conclusion:Liraglutide has a good application effect in patients with polycystic ovary syndrome.It can effectively improve the anti-Mullerian hormone and other hormone indicators and metabolic status,and it can also effectively increase the ovulation rate and pregnancy rate,and its clinical application value is higher.
作者
余艳芬
曾婉芝
黄镇
YU Yanfen;ZENG Wanzhi;HUANG Zhen(Dongcheng Hospital of Dongguan City,Dongguan 523100,China;不详)
出处
《中国医学创新》
CAS
2021年第15期152-155,共4页
Medical Innovation of China
